陰茎がん治療の世界市場-2023年～2030年

概要

世界の陰茎がん治療市場は、2022年に23億米ドルに達し、2023-2030年の予測期間中にCAGR 5.6％で成長し、2030年には32億米ドルに達すると予測されています。

陰茎がん治療市場は、陰茎がんの罹患率の増加、治療オプションの進歩、認知度、早期発見、政府の支援策、医療費の増加、個別化医療などの要因によって牽引されています。

より大きな腫瘍学市場のサブセットである陰茎がん治療市場は、この病気と診断された人々に医薬品や医療介入を提供することに重点を置いています。市場には、手術、放射線療法、化学療法、標的薬、免疫療法など、さまざまな種類の治療オプションがあります。

ダイナミクス

陰茎がんの罹患率の上昇が世界の陰茎がん治療市場の成長を促進する

Frontiers in 2022に掲載された論文によると、2020年に予想される陰茎がんの世界発生率は36,068例（10万人あたり0.92例）です。しかし、低開発国では悪性腫瘍の発生率は6.1症例/10万人に達する可能性があります。扁平上皮がん（SCC）は最も一般的な組織型であり、ほぼすべての発生に関与しています。根治手術の場合、リンパ節転移のない早期がんでは10年後の全生存率（OS）は96％であるのに対し、局所リンパ節転移や遠隔転移のある患者では5年後の全生存率はそれぞれ50％と12％です。

典型的な化学療法毒性と緩やかな生存成績により、進行病変の治療においてもネオアジュバント療法においても、細胞毒性化学療法は全身治療において重要な役割を果たしています。これは主にプラチナ製剤とタキサン系薬剤の併用レジメンで構成されています。

政府の取り組みが世界の陰茎がん治療市場の成長を促進

2022年にNature Reviews Urology誌に掲載された論文によると、国を超えて治療と治療を標準化し、陰茎がんなどのまれな泌尿生殖器がんにまつわる重大な臨床的ギャップを明らかにし、これらの患者の余命を延ばすためには、国際的な協力が緊急に必要です。世界稀少泌尿生殖器腫瘍学会（GSRGT）は、このような目的を達成することを目指しています。GSRGTの最初の目標は、まれな腫瘍の重要な発生源でありながら、以前は登録や研究から除外されていた発展途上国を取り込むことです。

例えば、南米、アフリカ、インド、アジアの3次医療施設は、世界各地からの迅速かつ徹底したデータ回収を可能にするために、北米および欧州の学術センターと協力しています。エビデンスに基づいた最善の治療を患者に提供するため、GSRGTは、陰茎がんに関する最新かつアクセスしやすい情報を広めるべく、各国の医師間の協力を促していく。これは、評判の高い医学会と協力することで達成されます。

陰茎がん治療に伴う副作用が世界の陰茎がん治療市場の成長を妨げる

化学療法薬は急速に分裂する細胞を標的とするため、がん細胞に対して有効です。しかし、骨髄（新しい血液細胞が産生される場所）、口や腸の粘膜、毛根など、体内の一部の細胞は分裂が早いです。これらの細胞は化学療法によって影響を受ける可能性があり、好ましくない影響が出ることがあります。

化学療法薬の種類、投与量、投与期間は、副作用に影響します。典型的な悪影響としては、脱毛、口内炎、食欲減退、嘔吐、吐き気、便秘または下痢、感染症のリスク増加（白血球の減少のため）、血小板数の低下によるあざや出血のしやすさ、疲労などがあります。

加えて、発がんや腫瘍の進行に関与する分子生物学やゲノム・エピゲノムの変化が十分に理解されていないことや、前向き臨床試験に患者を登録することが困難であることが、陰茎がんのような稀な腫瘍の治療の進歩を常に妨げてきました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 陰茎がん治療の罹患率の上昇
  • 抑制要因
    • 陰茎がん治療に伴う副作用
  • 機会
    • 技術進歩
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• アンメットニーズ
• 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争分析

第8章 人工知能分析

第9章 タイプ別

• 陰茎扁平上皮がん
• 陰茎腺がん
• 陰茎基底細胞がん
• その他

第10章 治療法別

• 化学療法
• 放射線療法
• 生物学的療法
• 光線力学的療法
• 抗生物質療法

第11章 エンドユーザー別

• 病院
• 専門クリニック
• 在宅医療
• その他

第12章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋
• 中東・アフリカ

第13章 競合情勢

• 競合シナリオ
• 製品ベンチマーク
• 企業シェア分析
• 主な発展と戦略

第14章 企業プロファイル

• Merck
  • 企業概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な動向
• GlaxoSmithKline
• Pfizer
• Bristol-Myers Squibb
• Roche
• Novartis
• Shanghai Junshi Biosciences Co., Ltd.
• Innovent Biologics
• Jiangsu Hengrui Medicine Co., Ltd.
• BeiGene Ltd.

第15章 付録

Overview

The Global Penile Cancer Treatment Market reached US$ 2.3 billion in 2022 and is expected to reach US$ 3.2 billion by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030.

The penile cancer treatment market is driven by factors such as increasing incidence of penile cancer, advancements in treatment options, awareness, and early detection, supportive government initiatives, increasing healthcare expenditure, and personalized medicine.

A subset of the larger oncology market, the penile cancer treatment market focuses on offering medicines and medical interventions to people who have been diagnosed with the disease. There are many different types of treatment options available on the market, including surgery, radiation therapy, chemotherapy, targeted medicines, and immunotherapy.

Dynamics

The Increasing Incidence of Penile Cancer Treatment is Driving the Global Penile Cancer Treatment Market Growth

As per the article published in Frontiers in 2022, the anticipated global incidence of penile cancer in 2020 is 36,068 cases (0.92 incidences per 100,000 individuals). However, the incidence of malignant tumors might be up to 6.1 cases/100,000 people in underdeveloped nations. Squamous cell carcinoma (SCC) is the most common histology and is responsible for almost all occurrences. With curative surgery, overall survival (OS) in individuals with early disease without nodal involvement is 96% in 10 years, compared to 50% and 12%, respectively, in 5 years for patients with regional node disease and distant metastatic disease.

With typical chemotherapeutic toxicities and modest survival outcomes, both in the treatment of advanced disease and in the neoadjuvant setting, cytotoxic chemotherapy plays a significant role in systemic treatment. It primarily consists of platinum and taxane combination regimens.

Government Initiatives are Driving the Global Penile Cancer Treatment Market Growth

As per the article published in Nature Reviews Urology in 2022, in order to standardize care and therapies across nations, uncover the critical clinical gaps around uncommon genitourinary cancers, such as penile cancer, and increase the life expectancy of these patients, international cooperation is urgently required. Global Society of Rare Genito-urinary Tumors (GSRGT) seeks to achieve these objectives. The initial goal of the GSRGT is to incorporate developing nations, which are a significant source of uncommon tumors but were previously excluded from registries and studies.

For instance, tertiary care facilities in South America, Africa, India, and Asia collaborate with academic centers in Europe and North America to enable rapid and thorough data recovery from all corners of the world. In order to provide patients with the best available evidence-based treatments, GSRGT will encourage cooperation between doctors from various nations in order to spread up-to-date and easily accessible information about penile cancer. This will be accomplished through working with reputable medical societies.

Side Effects Associated with Penile Cancer Treatment are Hampering the Global Penile Cancer Treatment Market Growth

Chemotherapy medications target rapidly dividing cells, which is why they are effective against cancer cells. However, some cells in the body divide quickly, including those in the bone marrow (where new blood cells are produced), the lining of the mouth and intestines, and the hair follicles. These cells can be impacted by chemotherapy, which may have unfavorable repercussions.

The type, dosage, and duration of the chemotherapy medications affect the adverse effects. Typical negative consequences include loss of hair mouth ulcers decrease in appetite, vomiting, nauseous, constipation or diarrhea, infection risk is increased (because of decreased white blood cell levels), and low blood platelet counts can cause easy bruising or bleeding as well as fatigue.

In addition, the lack of a thorough understanding of the molecular biology and genomic and epigenomic alterations involved in carcinogenesis and tumor progression, as well as the difficulty in enrolling patients for prospective clinical trials, have always hampered advances in the treatment of rare tumors like penile cancer.

Segment Analysis

The global penile cancer treatment market is segmented based on type, treatment, end-user and region.

The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 37.6% of the penile cancer treatment market in 2022. Cancer-curing medications are administered orally or by venous injections during systemic chemotherapy. These medications reach cancer cells all around the body via the bloodstream. Penile tumors that have migrated to distant organs or lymph nodes are the most common candidates for this treatment. Before surgery, tumors may be shrunk with chemotherapy to make them easier to remove.

Chemotherapy is administered by doctors in cycles, with a rest interval following each cycle to allow the body to heal. Chemotherapy cycles typically last 3 to 4 weeks. Cisplatin, Fluorouracil (5-FU), Paclitaxel (Taxol), Ifosfamide (Ifex), Mitomycin C, and Capecitabine (Xeloda) are a few of the medications used to treat penile cancer. In order to treat penile cancer that has progressed to lymph nodes or other organs, 2 or more of these medications are frequently combined. Cisplatin plus 5-FU is one of the most often used combos.

Geographical Penetration

North America Holds a Dominant Position in the Global Penile Cancer Treatment Market

North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. The active major players are driving the market in the North American region. Penile cancer is a rare form of cancer, especially in developed countries. Over 2000 new cases are reported annually in the United States, with rates of fewer than 1 per 100,000 men. However, there is a much higher occurrence in underdeveloped countries, where there is also a lack of therapeutic knowledge and access to care, which contributes to an unmet clinical need. The link with human papillomavirus infection, which may be present in as many as 50% of all penile carcinomas, is the most notable risk factor for penile cancer.

Older men are more likely to get penile cancer, and the incidence rate continually rises with age. Penile cancer most frequently affects men between the ages of 50 and 70, with a mean age of 67 in the United States of America.

Competitive Landscape

The major global players in the market include: Merck, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche, Novartis, Shanghai Junshi Biosciences Co., Ltd., Innovent Biologics, Jiangsu Hengrui Medicine Co., Ltd., and BeiGene Ltd. among others.

COVID-19 Impact Analysis

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war may affect the penile cancer treatment market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Healthcare workers are frequently displaced, medical supply lines are disrupted, and healthcare facilities are damaged during armed conflicts. The impacted people in Russia and Ukraine have less access to cancer detection and treatment options as a result.

Artificial Intelligence Impact Analysis

Artificial intelligence (AI) is increasingly being used in the penile cancer treatment market to improve various aspects of data analysis. AI can help oncologists create individualised treatment plans for patients with penile cancer. AI can make therapeutic recommendations that are specific to each patient by examining patient data, medical history, and the results of similar instances.

By Type

• Squamous Cell Cancer of Penis
• Adenocarcinoma of Penis
• Basal Cell Cancer of Penis
• Others

By Treatment

• Chemotherapy
• Radiation Therapy
• Biological Therapy
• Photodynamic Therapy
• Antibiotic Therapy

By End-user

• Hospitals
• Specialty Clinics
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico

• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe

• South America
  • Brazil
  • Argentina
  • Rest of South America

• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific

• Middle East and Africa

Why Purchase the Report?

• To visualize the global penile cancer treatment market segmentation based on the type, treatment, end-user and region and understand key commercial assets and players
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of penile cancer treatment market-level with all segments
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
• Product mapping available as excel consisting of key products of all the major players

The global penile cancer treatment market report would provide approximately 69 tables, 71 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by End-user
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Incidence of Penile Cancer Treatment
  • 4.1.2. Restraints
    • 4.1.2.1. Side effects associated with Penile Cancer Treatment
  • 4.1.3. Opportunity
    • 4.1.3.1. Technological advancements
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Unmet Needs
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers' Strategic Initiatives
• 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Type

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.1.2. Market Attractiveness Index, By Type
• 9.2. Squamous Cell Cancer of Penis*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Adenocarcinoma of Penis
• 9.4. Basal Cell Cancer of Penis
• 9.5. Others

10. By Treatment

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 10.1.2. Market Attractiveness Index, By Treatment
• 10.2. Chemotherapy*
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Radiation Therapy
• 10.4. Biological Therapy
• 10.5. Photodynamic Therapy
• 10.6. Antibiotic Therapy

11. By End-user

• 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
• 11.1.2. Market Attractiveness Index, By End-user
• 11.2. Hospitals*
  • 11.2.1. Introduction
  • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 11.3. Specialty Clinics
• 11.4. Homecare
• 11.5. Others

12. By Region

• 12.1. Introduction
  • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 12.1.2. Market Attractiveness Index, By Region
• 12.2. North America
  • 12.2.1. Introduction
  • 12.2.2. Key Region-Specific Dynamics
  • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.2.6.1. U.S.
    • 12.2.6.2. Canada
    • 12.2.6.3. Mexico
• 12.3. Europe
  • 12.3.1. Introduction
  • 12.3.2. Key Region-Specific Dynamics
  • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.3.6.1. Germany
    • 12.3.6.2. U.K.
    • 12.3.6.3. France
    • 12.3.6.4. Italy
    • 12.3.6.5. Spain
    • 12.3.6.6. Rest of Europe
• 12.4. South America
  • 12.4.1. Introduction
  • 12.4.2. Key Region-Specific Dynamics
  • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.4.6.1. Brazil
    • 12.4.6.2. Argentina
    • 12.4.6.3. Rest of South America
• 12.5. Asia-Pacific
  • 12.5.1. Introduction
  • 12.5.2. Key Region-Specific Dynamics
  • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
  • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 12.5.6.1. China
    • 12.5.6.2. India
    • 12.5.6.3. Japan
    • 12.5.6.4. Australia
    • 12.5.6.5. Rest of Asia-Pacific
• 12.6. Middle East and Africa
  • 12.6.1. Introduction
  • 12.6.2. Key Region-Specific Dynamics
  • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

• 13.1. Competitive Scenario
• 13.2. Product Benchmarking
• 13.3. Company Share Analysis
• 13.4. Key Developments and Strategies

14. Company Profiles

• 14.1. Merck*
  • 14.1.1. Company Overview
  • 14.1.2. Product Portfolio and Description
  • 14.1.3. Financial Overview
  • 14.1.4. Key Developments
• 14.2. GlaxoSmithKline
• 14.3. Pfizer
• 14.4. Bristol-Myers Squibb
• 14.5. Roche
• 14.6. Novartis
• 14.7. Shanghai Junshi Biosciences Co., Ltd.
• 14.8. Innovent Biologics
• 14.9. Jiangsu Hengrui Medicine Co., Ltd.
• 14.10. BeiGene Ltd.

LIST NOT EXHAUSTIVE

15. Appendix

• 15.1. About Us and Services
• 15.2. Contact Us